Avecho Biotechnology Ltd (ASX:AVE, OTC:AVEFF) CEO Dr Paul Gavin speaks with Proactive after announcing that the company is looking to raise approximately $11 million. Proceeds from the raise will be used to fund a pivotal Phase 3 clinical trial designed to test the company’s proprietary CBD soft-gel capsule for the treatment of insomnia.
Avecho Biotechnology CEO optimistic about phase III insomnia CBD trial
